Phase i study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 1, 2009, Pages 161-167

  Kim, Kevin B ^a   Hwu, Wen Jen ^a   Papadopoulos, Nicholas E ^a   Bedikian, Agop Y ^a   Camacho, Luis H ^a   Ng, Chaan ^a   Hernandez, Ingrid M ^a   Frost, Angela M ^a   Jack, Monica A ^a   Hwu, Patrick ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Chemotherapy; Cisplatin; Docetaxel; Melanoma; Phase I; Temozolomide

Indexed keywords

ANTIBIOTIC AGENT; CISPLATIN; DEXAMETHASONE; DOCETAXEL; GROWTH FACTOR; LORAZEPAM; SEROTONIN 3 ANTAGONIST; TEMOZOLOMIDE;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COUGHING; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; EPIPHORA; FATIGUE; FEMALE; FEVER; FOLLOW UP; HUMAN; INFECTION; LUNG EMBOLISM; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; NEUTROPENIA INFECTION; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SMELLING DISORDER; STAPHYLOCOCCUS INFECTION; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CISPLATIN; COHORT STUDIES; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; PULMONARY EMBOLISM; SKIN NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 67349197597     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0861-0     Document Type: Article

References (27)

1. CM Anderson AC Buzaid SS Legha 1995 Systemic treatments for advanced cutaneous melanoma Oncology (Huntingt) 9 1149 1158 discussion 1163-1144, 1167-1148
2. MR Middleton JJ Grob N Aaronson 2000 Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma J Clin Oncol 18 158 166 (Pubitemid 30036349)
3. Atkins MB (1997) The role of cytotoxic chemotherapeutic agents either alone or in combination with biological response modifiers. In: Kirkwood JK (ed) Molecular diagnosis, prevention and therapy of melanoma. Marcel Dekker, New York, p 219
4. AI Einzig H Hochster PH Wiernik 1991 A phase II study of taxol in patients with malignant melanoma Invest New Drugs 9 59 64
5. SS Legha S Ring N Papadopoulos M Raber RS Benjamin 1990 A phase II trial of taxol in metastatic melanoma Cancer 65 2478 2481 (Pubitemid 20168933)
6. AY Bedikian GR Weiss SS Legha 1995 Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy J Clin Oncol 13 2895 2899
7. Buzaid AC, Legha SS, Winn R (1993) Cisplatin, vinblastine, and dacarbazine versus dacarbazine alone in metastatic melanoma: preliminary results of a phase III Cancer Community Oncology Program (CCOP) trial. In Proc Am Soc Clin Oncol 389
8. PB Chapman LH Einhorn ML Meyers 1999 Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma J Clin Oncol 17 2745 2751 (Pubitemid 29415231)
9. SD Luikart GT Kennealey JM Kirkwood 1984 Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma J Clin Oncol 2 164 168 (Pubitemid 14138403)
10. MB Atkins KR O'Boyle JA Sosman 1994 Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma J Clin Oncol 12 1553 1560 (Pubitemid 24244989)
11. J Atzpodien E Lopez Hanninen H Kirchner 1995 Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen Eur J Cancer 31A 876 881
12. LE Flaherty W Robinson BG Redman 1993 A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma Cancer 71 3520 3525 (Pubitemid 23152659)
13. P Gibbs A Iannucci M Becker 2000 A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma Melanoma Res 10 171 179 (Pubitemid 30256880)
14. SS Legha AC Buzaid 1993 Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma Semin Oncol 20 27 32 (Pubitemid 24018751)
15. SS Legha S Ring A Bedikian 1996 Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha Ann Oncol 7 827 835 (Pubitemid 26345874)
16. SA Rosenberg JC Yang DJ Schwartzentruber 1999 Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b J Clin Oncol 17 968 975 (Pubitemid 29109330)
17. NJ Ives RL Stowe P Lorigan K Wheatley 2007 Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2, 621 patients J Clin Oncol 25 5426 5434 (Pubitemid 350232219)
18. Papadopoulos NE, Bedikian AY, Ring S, Kim KB, Camacho L, Eton O (2003) Phase II study of CTD (cisplatin, paclitaxel, DTIC) in metastatic melanoma (MM). In Proc Am Soc Clin Oncol, Chicago, IL 718 (abstr 2889)
19. MF Stevens JA Hickman SP Langdon 1987 Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5- tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine Cancer Res 47 5846 5852 (Pubitemid 18018717)
20. M Patel C McCully K Godwin FM Balis 2003 Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates J Neurooncol 61 203 207 (Pubitemid 36342297)
21. S Ostermann C Csajka T Buclin 2004 Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients Clin Cancer Res 10 3728 3736 (Pubitemid 38697606)
22. JD Hainsworth HA Burris 3rd FA Greco 1999 Weekly administration of docetaxel (Taxotere): summary of clinical data Semin Oncol 26 19 24 (Pubitemid 29368113)
23. GW Gladish DH Choe EM Marom BS Sabloff LD Broemeling RF Munden 2006 Incidental pulmonary emboli in oncology patients: prevalence, CT evaluation, and natural history Radiology 240 246 255 (Pubitemid 43902616)
24. F Tas A Argon H Camlica E Topuz 2005 Temozolomide in combination with cisplatin in patients with metastatic melanoma: a phase II trial Melanoma Res 15 543 548 (Pubitemid 44124267)
25. A Daponte PA Ascierto A Gravina 2005 Temozolomide and cisplatin in advanced malignant melanoma Anticancer Res 25 1441 1447 (Pubitemid 40546827)
26. D Bafaloukos D Tsoutsos H Kalofonos 2005 Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group Ann Oncol 16 950 957 (Pubitemid 40903922)
27. Hersh EM, O'Day S, Gonzalez R, Samlowski WE, Gordon MS, Hawkins MJ (2005) Open-label, multicenter, phase II trial of ABI-007 in previously treated and previously untreated patients with metastatic malignant melanoma. In American Society of Clinical Oncology, Orlando, FL Part I of II (1 June Supplement):7558